Silence Therapeutics plc

Ionis licensed global rights to Phase II polycythemia vera (PV) candidate sapablursen to Ono Pharmaceutical on 11 March. The deal provides near-term and longer-term revenue for a drug candidate the an

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. CytomX, Amgen Decision Follows January

While Silence Therapeutics’ zerlasiran and Lilly’s muvalaplin produced high response rates in patients with elevated lipoprotein(a), or Lp(a), in Phase II trials, both candidates are coming in behind

Cytokinetics Brought Down In the earlier halcyon days of biotech, the licensing of a biotech company’s lead drug to a big pharma partner would be associated with a substantial jump in the licensor’s